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We evaluated the eﬃcacy of percutaneous ethanol injection therapy (PEIT) as a therapeutic option for recurrence of secondary
hyperparathyroidism after subtotal parathyroidectomy in ESRD patients. Six patients underwent PEIT. A mean of 1.3 ± 0.8
ethanol injections was performed. Nodular volume was 1.5 ± 1.7cm3, and 2.8 ± 2.8cm3 of ethanol was injected per patient. After
ethanol injection PTH decreased signiﬁcantly (1897 ± 754 to 549 ± 863pg/mL (P<. 01)). There was also a reduction in serum
calcium, phosphorus and calcium-phosphorus product. A positive and signiﬁcant correlation was found between nodular volume
with ethanol injected and time from parathyroidectomy. Only one patient required hospitalization due to severe hypocalcaemia.
In other two cases, local discomfort and temporary mild dysphonia were registered. PEIT is an eﬀective treatment to control
recurrences of secondary hyperparathyroidism postsubtotal parathyroidectomy.
1.Introduction
Medical treatment is the main strategy to control secondary
hyperparathyroidism in patients with end-stage renal disease
(ESRD). However, in many cases this condition becomes
refractory to drug therapy [1]. For this reason, invasive
procedures such as intranodular ethanol injection (percu-
taneous ethanol injection therapy, PEIT) or parathyroidec-
tomy have been proposed [2, 3]. The type of procedure used
depends of the intact PTH levels, number and size of the
glands involved, and their ultrasonographic visibility.
In the case of subtotal parathyroidectomy, patient keeps
between 1/4 and 1/2 of the gland. Over time, if the
conditions causing hyperparathyroidism persist, gland may
grow and increase again the levels of intact PTH. Moreover,
after surgery a high percentage of patients (12 to 30%)
may develop recurrent or persistent hyperparathyroidism
[4]. Thus, the patient will suﬀer the clinical consequences
of hyperparathyroidism once again (i.e., high morbidity-
mortality), despite surgery. When the residual nodule is
visible with ultrasonography, its destruction is possible with
ethanol injection until the desired levels of intact PTH and
calcium phosphorus product are reached [5].
We presented a series of patients with recurrent hyper-
parathyroidism postsubtotal parathyroidectomy who were
adequately managed with PEIT.
2.SubjectsandMethods
The study included six patients with ESRD under chronic
hemodialysis and diagnosis of recurrent secondary hyper-
parathyroidism. All the patients had history of secondary
hyperparathyroidism that became refractory to the medical
treatment. Because, this condition, all patients had under-
gone subtotal parathyroidectomy with neck exploration
searching for the four parathyroid glands and removing the2 International Journal of Nephrology
Table 1: Demographic and clinical data. Mean±SD.
Characteristic Total patients (N = 6)
Age to PEIT, years 47.4±11.1
Gender, female/male 3/3
Time from HD to PTx, months 82.0 ± 44.0
Time from PTx to PEIT, months 26.4±45.7
ESRD: end-stage renal disease, HD: hemodialysis, PEIT: percutaneous
ethanol injection treatment, and PTx: parathyroidectomy.
three glands that were macroscopically more aﬀected and
the 1/2 or 3/4 part of the gland with healthier aspect. No
autotransplantation of parathyroid tissue was performed in
any of the cases.
The indication of the treatment with PEIT was recurrent
secondary hyperparathyroidism with levels of intact PTH
higher than 300pg/mL in patients who had undergone a
subtotal parathyroidectomy and presence of at least one
parathyroid nodule visible in the ultrasonography.
The mean age of the population was 47.4±11.1 years
(median 47, min36–max64), 3 patients were female, and
the mean time elapsed from the initiation of hemodialysis
therapy to the PEIT was 108.4±58.6 months (median
89, min36–max180). Three patients had ESRD secondary
to chronic glomerulonephritis, one case was associated to
eclampsia, and other two; the cause of ESRD was unknown.
Before PEIT, medical management for hyperparathy-
roidism included control of hyperphosphatemia with a low
phosphorous diet, oral phosphate binders (calcium, seve-
lamer, and aluminum), more intensive dialysis and in cases
withoutcontraindicationsoral/ivcalcitriol.Similarmeasures
were used after PEIT in order to maintain an adequate
calcium-phosphorus metabolism and to avoid recurrence of
hyperparathyroidism.
2.1. Study Procedures. All injections were administered by
the same qualiﬁed interventional radiologist and performed
under ultrasonographic guidance. Nodular volume and size
of all glands treated with PEIT were larger than 0.1cm3 as
calculated by ultrasonographic evaluation of their 3 longest
axes. A 95% ethanol solution was used for PEIT with a total
alcohol volume calculated to be at least the same as the
nodule volume. A modiﬁed needle for ethanol injection with
small side holes, easily recognized under ultrasonography
and local anesthesia with lidocaine in an ambulatory facility
was used. The treatment was considered successful when
the levels of intact PTH decreased from 150 to 300pg/mL,
as suggested by K/DOQI guidelines [6]. Major and minor
complications related to the proceeding were registered in
each patient. All the patients sign the informed consent in
order to carry out the procedure.
2.2. Biochemical Measurements. Biochemical assays were
performed immediately before the ﬁrst PEIT session (basal)
and between 1 and 7 days after the last PEIT session (ﬁnal).
Serum creatinine, calcium, phosphorus, and alkaline
p h o s p h a t a s ew e r em e a s u r e dw i t ha na u t o a n a l y z e r( H i t a c h i
917: Hitachi, Ltd., Tokyo, Japan), and intact iPTH by electro-
chemiluminescence (Nichol’s Institute, San Juan Capistrano,
Calif, USA).
2.3. Statistical Analyses. Results are expressed as mean ±
standard deviation. Statistical analysis for continuous vari-
ables was performed with Wilcoxon nonparametric test.
Correlations between variables were calculated according to
Pearson’s coeﬃcient. A value of P<. 05 was considered as
signiﬁcant.
3. Results
All patients had a residual parathyroid nodules identiﬁed
by ultrasonography, and PEIT was performed 26.4±45.7
months (median7, min2–max108), after parathyroidec-
tomy (Table 1).
In one patient, an ectopic parathyroid gland located in
anterosuperior mediastinum behind the manubrium was
detected. This patient had undergone parathyroid surgery
twice. In the ﬁrst surgery, 3 parathyroid glands were
removed, and in the second surgery some months later, glan-
dular tissue was not identiﬁed. The patient did not accept to
undergo another surgery when an ectopic parathyroid gland
was detected by scintigraphy. In the remaining 5 patients, the
ultrasonography detected residual and enlarged parathyroid
tissue in the site where a small portion of parathyroid gland
had been left during the surgical procedures.
In average, 1.3±0.8 ethanol injections were made per
patient and a mean of 2.8±2.8cm3 of ethanol was injected.
T h ea v e r a g en o d u l a rv o l u m ew a s1 . 5±1.7cm3, although the
volumes were very diﬀerent among patients (0.2 to 4.5cm3)
(Table 2).
The mean levels of PTH had a signiﬁcant decrease at
ﬁnal control, falling from 1897±754 to 549±863pg/mL
(P<. 01) (Figure 1).
The average decrease of intact PTH was 72±33% (range
8,0–96,6%). There was also a decrease in the levels of serum
calcium, phosphorus, and calcium-phosphorus product,
being signiﬁcant in the last two. A positive and signiﬁcant
correlation was found between the total nodular volume, the
volume of ethanol used in each session (r = 0.85; P<. 02),
and the time from parathyroidectomy (r = 0.87; P<. 02)
(Figure 2).
In one patient, the expected result on intact PTH
decrease was not achieved. This patient showed a reduction
of 8% in the level of PTH and maintained the levels of
calcium and phosphorus above the recommended level by
K/DOQI guidelines after PEIT [6]. This procedure was
performed on a small nodule of only 0.2cm3,a n dP E I T
had to be stopped prematurely due to technical problems to
visualize and identify the parathyroid nodule. Ectopic gland
was not found by a scintigraphy.
When analyzing the degree of compliance with the
parameters of mineral metabolism recommended by
K/DOQI guidelines (intact PTH, calcium, phosphorus, and
Ca×P product), it was observed that prior to the PEIT,
no patients were in agreement with the 4 parameters; 2
patients meet 3 criteria, 2 patients fulﬁll only one, and theInternational Journal of Nephrology 3
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Figure 1: Intact parathyroid hormone, calcium, phosphate, and
calcium×phosphorous product levels pre- and post-PEIT.
remaining 2 patients did not satisfy any of the recommended
parameters. At the ﬁnal control post-PEIT, one patient meet
the 4 criteria, 4 patients fulﬁll 3 criteria, while the remaining
patient did not satisfy any of the parameters recommended
by K/DOQI [6]. This last patient was the one who did not
properly respond to PEIT (Table 2).
A l lt h ep r o c e d u r e sw e r ep e r f o r m e do na no u t p a t i e n t
basis, and only one patient required hospitalization after the
procedure due to severe hypocalcaemia that reverted with
calcium replacement by intravenous administration. In two
cases, only local discomfort and temporary mild dysphonia
were registered.
4. Discussion
In several clinical settings, severe secondary hyperparathy-
roidism can be controlled quickly and safely by using
PEIT. This technique is not only an alternative to surgical
parathyroidectomy,butalsoanimportantadjuncttomedical
management[7].Ithasprovedtobeusefulforpatientseither
on dialysis or after renal transplantation in circumstances in
which the disease is considered to be resistant to medical
treatment or when the surgical risk is high [8–10].
Secondary hyperparathyroidism is a common complica-
tion of the long-term dialysis [11, 12]. The DOPPS inter-
national study has demonstrated that 26.3% of the patients
from the participant countries have hyperparathyroidism
[13]. It has been shown to predominate in Latin American
countries [12, 14].
Secondary hyperparathyroidism is managed successfully
with medical treatment in most of the patients, but the
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Figure 2: Correlation between total nodular volume, total volume
of ethanol used, and the time from parathyroidectomy (PTx).
disease becomes refractory to the therapy in a considerable
number of them [1] .T h e s ei sm o r ef r e q u e n ti ns u b j e c t sw i t h
severe, long-term hyperparathyroidism and with nodular
hyperplasia in enlarged glands. This glands have a lower-
density receptors for calcitriol and calcium both needed to
respondtothetreatment[1,15].Therefore,inthesepatients,
it is necessary to consider the possibility of using invasive
treatment [2].
Surgical parathyroidectomy is indicated when the
patients who do not respond to the medical treatment
present signs of osteitis ﬁbrosa, extraosseous calciﬁcations,
hypercalcemia or hyperphosphatemia, with more than
2 glands visible with ultrasonography, and dramatically
increased levels of intact PTH [16, 17]. Although in most
of the patients there is an important decrease of PTH levels,
a considerable number of them ranging from 10 to 30%
suﬀer a recurrence of secondary hyperparathyroidism, and
it is required, in many cases, to undergo more complicated
reoperations [18].
Potential factors related with recurrent postsurgical
hyperparathyroidism are the persistence of the conditions
causing hyperparathyroidism such as the presence of aInternational Journal of Nephrology 5
residual portion of parathyroid gland, which is present
when either a subtotal or a total parathyroidectomy with
autotransplantation is performed. In rare cases, an ectopic
gland that was not obvious in presence of the other activated
parathyroid glands may evidence increased size and activity.
Once recurrence occurred, the levels of PTH will dramati-
cally increase again with their known consequences on the
skeleton and cardiovascular system. The therapeutic possi-
bilities of these cases are reduced. These residual nodules are
refractory to the medical treatment because they do not have
the adequate concentration of both calcium and calcitriol
receptors [19] .An e ws u r g i c a lp r o c e d u r ei m p l i e ss o m e
risks because of the high morbidity of these patients, some
technical complications in a sector with a previous surgery
that usually presents periglandular ﬁbrosis and with the only
possibility of removing all the residual parathyroid tissue,
which causes hypoparathyroidism in most of the cases.
In the patients of the present series, surgical resection of
theremnantparathyroidtissuewasnotrecommendeddueto
a high risk to produce severe and permanent hypoparathy-
roidism causing adynamic bone disease with cardiovascular
calciﬁcations. Cryopreservation of parathyroid tissue is an
option to prevent this complication but the technique is not
available in our center.
In some cases, Lomonte et al. have described the success-
ful use of cinacalcet inducing the suppression of intact
PTH secretion by the parathyroid glands [20]. However, in
order to achieve this aim, it is necessary to have an adequate
quantity of calcium receptors in the remaining parathy-
roid tissue, which is not the rules in cases of secondary
hyperparathyroidism refractory to the medical treatment
[19]. Although cinacalcet represents a valid option for these
patients, it is not available for use in many countries, for
example, in Latin America countries.
Since the early 1980s, PEIT has been proposed as a less
invasive alternative to parathyroidectomy [21]. The basis
of this therapy is that enlarged parathyroid glands with
nodular hyperplasia are destroyed selectively by ethanol
injection [22]. We recently reported in dialysis patients a
signiﬁcant decrease in PTH, with improvement in serum
calcium, phosphate, and Ca×P product. These results were
signiﬁcantly correlated with PTH levels and nodular volume
[9]. Patients under dialysis, with large nodule volume and
very high PTH levels, obtained good results after PEIT [9].
Failure to PEIT could be related to a wrongly selection of
gland for ethanol injection. Poor results have been obtained
in glands with diﬃcult accessibility, diﬀuse hyperplasia,
ectopic glands, and ultrasonographic poor visibility such as
in the case of patient number 6.
It has also proved to be useful in cases of hyper-
parathyroidism after renal transplantation, complicated with
hypercalcemia and hypophosphatemia with few and minor
complications. In this setting, parathyroidectomy is consid-
ered too aggressive for controlling the hyperparathyroidism,
and was carries out [10].
At the present, there are no data about the use of PEIT
inpatientswithrecurrenthyperparathyroidismaftersubtotal
parathyroidectomy, so that this is the ﬁrst series of patients
reporting this technique in this setting [5].
All the patients included in this study suﬀered from a
severe secondary hyperparathyroidism and had previously
undergone at least one subtotal parathyroid surgery. After
PEIT, the level of intact PTH showed a signiﬁcant decrease
with a mean rate of 72%. Four patients reached levels of
intactPTHwithintheparametersrecommendedbyK/DOQI
guidelines. In one case, the level was close to the suggested
value with 311pg/mL and in the remaining patient no
adequate response was achieved (Table 2).
In summary, as it was previously demonstrated for
patients undergoing dialysis and transplantation, PEIT has
proved to be a useful technique for the management of
recurrent postsurgical secondary hyperparathyroidism. It
was useful to rapidly resolve a common complication of
parathyroidectomy at a low cost and with a high level of
safety. Results of the present series suggest that PEIT should
beconsideredforthetreatmentofrecurrentpostsurgicalsec-
ondary hyperparathyroidism particularly when calcimimetic
and cryopreservation are not available. Prospective and
controlled trials comparing PEIT with others therapies are
needed to conﬁrm their role in the management of this
disease.
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